1. Home
  2. RGLS vs CRNC Comparison

RGLS vs CRNC Comparison

Compare RGLS & CRNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGLS
  • CRNC
  • Stock Information
  • Founded
  • RGLS 2007
  • CRNC N/A
  • Country
  • RGLS United States
  • CRNC United States
  • Employees
  • RGLS N/A
  • CRNC N/A
  • Industry
  • RGLS Biotechnology: Pharmaceutical Preparations
  • CRNC EDP Services
  • Sector
  • RGLS Health Care
  • CRNC Technology
  • Exchange
  • RGLS Nasdaq
  • CRNC Nasdaq
  • Market Cap
  • RGLS 106.7M
  • CRNC 123.7M
  • IPO Year
  • RGLS 2012
  • CRNC N/A
  • Fundamental
  • Price
  • RGLS $1.59
  • CRNC $3.11
  • Analyst Decision
  • RGLS Strong Buy
  • CRNC Hold
  • Analyst Count
  • RGLS 6
  • CRNC 8
  • Target Price
  • RGLS $10.33
  • CRNC $6.33
  • AVG Volume (30 Days)
  • RGLS 391.3K
  • CRNC 1.8M
  • Earning Date
  • RGLS 11-11-2024
  • CRNC 11-25-2024
  • Dividend Yield
  • RGLS N/A
  • CRNC N/A
  • EPS Growth
  • RGLS N/A
  • CRNC N/A
  • EPS
  • RGLS N/A
  • CRNC N/A
  • Revenue
  • RGLS N/A
  • CRNC $357,463,000.00
  • Revenue This Year
  • RGLS N/A
  • CRNC $12.48
  • Revenue Next Year
  • RGLS N/A
  • CRNC N/A
  • P/E Ratio
  • RGLS N/A
  • CRNC N/A
  • Revenue Growth
  • RGLS N/A
  • CRNC 31.49
  • 52 Week Low
  • RGLS $1.08
  • CRNC $2.34
  • 52 Week High
  • RGLS $3.79
  • CRNC $21.67
  • Technical
  • Relative Strength Index (RSI)
  • RGLS 53.16
  • CRNC 53.73
  • Support Level
  • RGLS $1.39
  • CRNC $2.76
  • Resistance Level
  • RGLS $1.68
  • CRNC $3.53
  • Average True Range (ATR)
  • RGLS 0.12
  • CRNC 0.23
  • MACD
  • RGLS 0.01
  • CRNC 0.00
  • Stochastic Oscillator
  • RGLS 68.97
  • CRNC 60.00

About RGLS Regulus Therapeutics Inc.

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

About CRNC Cerence Inc.

Cerence Inc is a United States-based software company. It is involved in developing mobility-based solutions for drivers and their cars. The customers include all automobile original equipment manufacturers, or OEMs, or their tier 1 suppliers. The company's revenue is generated by selling software licenses and cloud-connected services. Geographically, it derives a majority of its revenue from the United States and also has a presence in Other Americas; Germany; Other Europe, the Middle East, Africa; Japan, and Other Asia-Pacific.

Share on Social Networks: